By Professor Jason Grebely

Journal articles

Grebely J; Matthews GV; Lloyd AR; Dore GJ, 2013, 'Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: Feasibility and future requirements', Clinical Infectious Diseases, 57, pp. 1014 - 1020, http://dx.doi.org/10.1093/cid/cit377

Hajarizadeh B; Grebely J; Dore GJ, 2013, 'Epidemiology and natural history of HCV infection', Nature Reviews Gastroenterology and Hepatology, 10, pp. 553 - 562, http://dx.doi.org/10.1038/nrgastro.2013.107

Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ, 2013, 'Assessment and treatment of hepatitis c virus infection among people who inject drugs in the opioid substitution setting: ETHOS study', Clinical Infectious Diseases, 57, pp. s62 - s69, http://dx.doi.org/10.1093/cid/cit305

Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS, 2013, 'Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: A randomized controlled trial', Clinical Infectious Diseases, 57, http://dx.doi.org/10.1093/cid/cit327

Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ, 2013, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', Clinical Infectious Diseases, 57, pp. s129 - s137, http://dx.doi.org/10.1093/cid/cit302

Aspinall EJ; Corson S; Doyle JS; Grebely J; Hutchinson SJ; Dore GJ; Goldberg DJ; Hellard ME, 2013, 'Treatment of hepatitis c virus infection among people who are actively injecting drugs: A systematic review and meta-analysis', Clinical Infectious Diseases, 57, pp. s80 - s89, http://dx.doi.org/10.1093/cid/cit306

Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'Sequencing of the Hepatitis C Virus: A Systematic Review', PLoS ONE, 8, pp. e67073, http://dx.doi.org/10.1371/journal.pone.0067073

Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, 57, pp. 2124 - 2134, http://dx.doi.org/10.1002/hep.26263

Deans GD; Raffa JD; Lai C; Fischer B; Krajden M; Amin J; Walter SR; Dore GJ; Grebely J; Tyndall MW, 2013, 'Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada', CMAJ Open, 1, pp. e68 - e76, http://dx.doi.org/10.9778/cmajo.20130002

Grebely J; Bilodeau M; Feld JJ; Bruneau J; Fischer B; Raven JF; Roberts E; Choucha N; Myers RP; Sagan SM; Wilson JA; Bialystok F; Lorne Tyrrell D; Houghton M; Krajden M, 2013, 'The Second Canadian Symposium on Hepatitis C Virus: A call to action', Canadian Journal of Gastroenterology, 27, pp. 627 - 632, http://dx.doi.org/10.1155/2013/242405

Grebely J; Oser ML; Taylor L; Dore GJ, 2013, 'Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels', Journal of Infectious Diseases, 207, pp. S19 - S25, http://dx.doi.org/10.1093/infdis/jis928

Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G; Michalk M; Malik B; McClure P; Smith S; Sheridan D; Snape E; Fragomeli V; Norris R; How-Chow D; Jonsson JR; Barrie H; Stelzer-Braid S; Fletcher S; Applegate T; Grebely J; Matthews G; Bharadwaj M; Smedile A, 2013, 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, 14, pp. 286 - 290, http://dx.doi.org/10.1038/gene.2013.15

Post J; Arain A; Lloyd AR; Grebely J; Dore G, 2013, 'Enhancing Assessment and Treatment Hepatitis C in the Custodial Setting', Clinical Infectious Diseases, 57, pp. S70 - S74, http://dx.doi.org/10.1093/cid/cit264

Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, 31, pp. 33 - 33

Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, 31, pp. 34 - 34

Hajarizadeh B; Grebely J, 2012, 'HIV and Liver Disease', PRACTICAL GASTROENTEROLOGY, 36, pp. 46 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000421778800005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sacks-davis R; Horyniak D; Grebely J; Hellard M, 2012, 'Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review', International Journal of Drug Policy, 23, pp. 176 - 184, http://dx.doi.org/10.1016/j.drugpo.2011.08.002

Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, 57, pp. 1349 - 1360, http://dx.doi.org/10.1016/j.jhep.2012.07.007

Grebely J; Morris M; Rice T; Bruneau J; Cox AL; Kim A; McGovern B; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Prins M; Dore GJ; Page K, 2012, 'Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.', International Journal of Epidemiology, in press, pp. 1-11, http://dx.doi.org/10.1093/ije/dys167

Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M; Van Beek I; Amin J; Dolan K; Rawlinson W; Flynn J; Marks P; Acraman B; Bloch M; Li H; Madden A; George J, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Grebely J; Prins M; Hellard M; Cox AL; Osburn WO; Lauer G; Page K; Lloyd AR; Dore GJ; Maher L, 2012, 'Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine', Lancet Infectious Diseases, 12, pp. 408 - 414, http://dx.doi.org/10.1016/S1473-3099(12)70010-5

Sacks-davis R; Daraganova G; Aitken CK; Higgs P; Tracy L; Bowden S; Jenkinson R; Rolls D; Pattison P; Robins G; Grebely J; Barry A; Hellard M, 2012, 'Hepatitis C Virus Phylogenetic Clustering Is Associated with the Social-Injecting Network in a Cohort of People Who Inject Drugs', PLoS ONE, 7, pp. Article number e47335, http://dx.doi.org/10.1371/journal.pone.0047335

Grebely J; Pham ST; Matthews G; Petoumenos K; Bull RA; Yeung B; Rawlinson WD; Kaldor JM; Lloyd AR; Hellard M; Dore GJ; White PA; Bull ; Dolan K, 2012, 'Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection', Hepatology, 55, pp. 1058 - 1069, http://dx.doi.org/10.1002/hep.24754

Treloar C; Hull PB; Dore GJ; Grebely J, 2012, 'Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs', Drug and Alcohol Review, 31, pp. 918 - 924, http://dx.doi.org/10.1111/j.1465-3362.2012.00468.x

Grebely J; Talwalkar J, 2012, 'Recognizing and preventing death from compensated cirrhosis in the community.', Liver International, 32, pp. 2 - 4, http://dx.doi.org/10.1111/j.1478-3231.2011.02627.x

Vickerman P; Grebely J; Dore GJ; Sacks-davis R; Page K; Thomas DL; Osburn WO; Cox AL; Aitken CL; Hickman M; Hellard M; Maher L, 2012, 'The more you look, the more you find: Effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design', Journal of Infectious Diseases, 205, pp. 1342 - 1350, http://dx.doi.org/10.1093/infdis/jis213

Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719

Grebely J; Dore GJ, 2012, 'What is killing people with hepatitis C virus infection?', Seminars in Liver Disease, 31, pp. 331 - 339, http://dx.doi.org/10.1055/s-0031-1297922

Sacks-Davis R; Daraganova G; Aitken C; Higgs P; Tracy L; Bowden D; Robins G; Pattison P; Grebely J; Barry A; Hellard M, 2011, '1178 MOLECULAR EPIDEMIOLOGY OF HEPATITIS C IN A SOCIAL NETWORK OF YOUNG PEOPLE WHO INJECT DRUGS', Journal of Hepatology, 54, pp. S465 - S466, http://dx.doi.org/10.1016/s0168-8278(11)61180-x

Grebely J; Matthews G; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber P; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2011, 'Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users', Journal of Hepatology, 55, pp. 76 - 85, http://dx.doi.org/10.1016/j.jhep.2010.10.033

Grebely J; Dore GJ, 2011, 'An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community', Hepatology, 54, pp. 2259 - 2261

Treloar C; Hull PB; Bryant J; Hopwood MN; Grebely J; Lavis YM, 2011, 'Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs', Drug and Alcohol Dependence, 116, pp. 52 - 56, http://dx.doi.org/10.1016/j.drugalcdep.2010.11.018

Grebely J; Bryant J; Hull PB; Hopwood MN; Lavis YM; Dore GJ; Treloar C, 2011, 'Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.', Journal of Viral Hepatitis, 18, pp. 104 - 116, http://dx.doi.org/10.1111/j.1365

Grebely J; Dore GJ, 2011, 'Hepatitis C: Enhancing treatment for hepatitis C among drug users', Nature Reviews Gastroenterology and Hepatology, 8, pp. 11 - 13, http://dx.doi.org/10.1038/nrgastro.2010.186

Smith KR; Suppiah V; O''Connor K; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Matthews G; Irving W; Powell E; Riordan S; Ahlensteil G; Stewart GJ; Bahlo M; Booth DR; George J, 2011, 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort', Genome Medicine, 3, pp. 57

Grebely J; Raffa JD; Lai C; Kerr T; Fischer B; Krajden M; Dore GJ; Tyndall MW, 2011, 'Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents', Journal of Viral Hepatitis, 18, pp. 32 - 41, http://dx.doi.org/10.1111/j.1365-2893.2010.01279.x

Grebely J; Tyndall M, 2011, 'Management of HCV and HIV infections among people who inject drugs', Current opinion in HIV & AIDS, 6, pp. 501 - 507, http://dx.doi.org/10.1097/COH.0b013e32834bcb36

Matthews G; Pham STP; Hellard M; Grebely J; Zhang L; Oon A; Marks P; Van Beek IA; Rawlinson WD; Kaldor JM; Lloyd AR; Dore GJ; White PA, 2011, 'Patterns and characteristics of Hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C', Clinical Infectious Diseases, 52, pp. 803 - 811, http://dx.doi.org/10.1093/cid/ciq200

Grebely J; Dore GJ, 2011, 'Prevention of hepatitis C virus in injecting drug users: A narrow window of opportunity', Journal of Infectious Diseases, 203, pp. 571 - 574

Grebely J; Matthews G; Dore GJ, 2011, 'Treatment of acute HCV infection', Nature Reviews Gastroenterology and Hepatology, 8, pp. 265 - 274, http://dx.doi.org/10.1038/nrgastro.2011.32

Grebely J; Dore GJ, 2011, 'What is killing people with HCV infection?', Seminars in Liver Disease, 31, pp. 331 - 339

Grebely J; Matthews GV; Petoumenos K; Dore GJ, 2010, 'Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection', Journal of Viral Hepatitis, 17, pp. 896, http://dx.doi.org/10.1111/j.1365-2893.2009.01256.x

Dore G; Grebely J; Gillman A; Thein R; Day C; Ryan L; Treloar C; Haber P, 2010, 'PRESENTER 1: OVERVIEW OF TREATMENT OF HEPATITIS C (HCV) IN THE OPIATE PHARMACOTHERAPY SETTING AND THE ENHANCING TREATMENT OF HEPATITIS C IN THE OPIATE SUBSTITUTION SETTING (ETHOS) PARTNERSHIP INITIATIVE', DRUG AND ALCOHOL REVIEW, 29, pp. 21 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000284895600048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Grebely J; Bryant J; Hull P; Hopwood M; Dore G; Treloar C, 2010, 'PRESENTER 2: SPECIALIST ASSESSMENT AND TREATMENT OF HEPATITIS C VIRUS INFECTION AMONG INJECTION DRUG USERS IN NEW SOUTH WALES, AUSTRALIA', DRUG AND ALCOHOL REVIEW, 29, pp. 21 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000284895600049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; Van Beek IA; McCaughan G; White PA; French R; Rawlinson WD; Lloyd AROLA; Kaldor JM; Dolan K, 2010, 'Effective treatment of injecting drug users with recently acquired hepatitis C virus infection', Gastroenterology, 138, pp. 123 - 135, http://dx.doi.org/10.1053/j.gastro.2009.09.019

Grebely J; Petoumenos K; Matthews G; Haber PS; Marks P; Lloyd AROLA; Kaldor JM; Dore GJ; Hellard M; Dolan K, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study', Drug and Alcohol Dependence, 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015

Grebely J; Knight E; Genoway K; Viljoen M; Khara M; Elliott D; Gallagher L; Storms M; Raffa J; DeVlaming S; Duncan F; Conway B, 2010, 'Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support', European Journal of Gastroenterology and Hepatology, 22, pp. 270 - 277

Grebely J; Petoumenos K; Hellard M; Matthews G; Suppiah V; Applegate TL; Yeung B; Marks P; Rawlinson WD; Lloyd AROLA; Booth D; Kaldor JM; George J; Dore GJ; Amin J; Cameron B; Acraman B; Dolan K; Bloch M; Van Beek I; Li H; Madden A, 2010, 'Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection', Hepatology, 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850

Grebely J; Knight E; Ngai T; Genoway K; Raffa J; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B, 2010, 'Reinfection with hepatitis C virus following sustained virological response in injection drug users', Journal of Gastroenterology and Hepatology, 25, pp. 1281 - 1284, http://dx.doi.org/10.1111/j.1440-1746.2010.06238.x

Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, 28, pp. A27 - A27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page